67药品被重点监控,喜炎平、血栓通、小牛血……

2017-12-02 禹鑫 赛柏蓝

12月1日,一份广州卫计委《关于建立全市医疗机构重点药品监控制度的通知》,在业界传播。通知显示,其发布日期为11月28日。

67药品被广州重点监控,喜炎平、血栓通、小牛血......

并且,广州各医院的重点监控药品,要向社会公开!

12月1日,一份广州卫计委《关于建立全市医疗机构重点药品监控制度的通知》,在业界传播。通知显示,其发布日期为11月28日。



▍67药品上监控目录,数量多

67药品被列入广州重点监控指导目录,化学药37个、中成药29个、另一个是生物制剂——鼠神经生长因子(详见附件)。翻阅几年来的监控目录,广州这个数量要超过安徽、四川、苏州等地,可能和各地市场的差异有关。

文件要求广州市各医疗机构,结合本医疗机构前6个月使用金额排名前30位,或前6个月使用金额排名前100位,且使用量与上6个月相比增幅在20%以上的药品,以及本机构认为有必要列入重点监控的其他药品进行遴选,编制重点药品监控目录。

包括能量及营养成分补充药物、免疫增强剂、脑循环与促智药、活血化瘀类药物、抗肿瘤辅助药。

▍医院的重点监控目录,要向社会公开

同时要求,医院药占比在30%以上的,应适当扩大重点药品监控目录范围。各单位可参考《广州市药品重点监控指导目录》,按照“应控尽控"的原则,研究确定本院重点药品监控目录。并于2017年12月31曰前报广州卫计委医政处备案。

各医疗机构要将确定的重点监控药品目录(包括药品通用名、剂型、规格、生产企业等)在本单位门户网站公布。

如果没记错的话,将重点监控目录放在医院门户网站上,供公众查看,应该是多年来的第一例。

▍连续两个月用量增长超30%,停药

此外,无特殊原因使用率异常增大的重点监控药品,要实施预警通报和重点监控管理,必要时可会同本单位纪检监察部门进行约谈。

对连续两个月用量增长超过30%,或连续三个月用量增长超过 20%,或连续四个月用量增长超过10%的药品,可以暂停或限量供应,暂停后确需使用的,应建立审批或会诊程序。

▍控费大爆发

有关控费,这一段呈爆发态势。

日前,贵州、四川卫计委先后都发布紧急通知,要求省内医院严格控费。随后就传出了两省不少三级医院停药、限药的消息。

广州市的动作,可以参照11月底,业界传出的广东省卫计委一份“加急”《关于进一步加强医疗机构药品控费工作的通知》的背景。在此之下,广州市发出的重点监控通知,响应上级、直至控费。

另外,广州市卫计委给出的67药品目录,只是作为参考,也给不同情况的医院,留出了自由调整的空间。

附:



附:

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (20)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=333170, encodeId=148b3331e039, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/07/07/1452f599cfa32a40733fa16ccf8ff86f.jpg, createdBy=d7452387169, createdName=Sometimes1575, createdTime=Sat Jul 21 16:38:48 CST 2018, time=2018-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1668094, encodeId=49e9166809405, content=<a href='/topic/show?id=598b40158ff' target=_blank style='color:#2F92EE;'>#喜炎平#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40158, encryptionId=598b40158ff, topicName=喜炎平)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e0f926261460, createdName=tamgche, createdTime=Mon Jun 04 02:58:00 CST 2018, time=2018-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1648669, encodeId=44651648669cc, content=<a href='/topic/show?id=e037891284c' target=_blank style='color:#2F92EE;'>#血栓通#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89128, encryptionId=e037891284c, topicName=血栓通)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=051423632604, createdName=cathymary, createdTime=Fri Dec 08 09:58:00 CST 2017, time=2017-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1949080, encodeId=27b4194908032, content=<a href='/topic/show?id=72459589567' target=_blank style='color:#2F92EE;'>#重点监控#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95895, encryptionId=72459589567, topicName=重点监控)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93e223, createdName=bluefate121, createdTime=Tue Dec 12 22:58:00 CST 2017, time=2017-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=273265, encodeId=0d8b2e326551, content=谢谢分享.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160304/IMG56D94856B1B5D6405.jpg, createdBy=27931687771, createdName=一个字-牛, createdTime=Thu Dec 28 16:59:15 CST 2017, time=2017-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=267237, encodeId=b29226e23769, content=好好好学习学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM6DGOvNrRdcib3UmzMgpEQpl0ENSJScphsFtdgfibXX1g1IuEYGCjP23UqCd52TxTpSZibtPiclyusaHicnNXd78alaia19Qy1nAFo18/0, createdBy=50381491660, createdName=zwjnj2, createdTime=Wed Dec 06 10:59:03 CST 2017, time=2017-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=266347, encodeId=a60526634e1b, content=这些药品是谁审批.让进入临床的, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/21/9461f3b3c9f14e1d844256cdd08f2cf3.jpg, createdBy=a30f1426910, createdName=swfzhanggui, createdTime=Sun Dec 03 05:06:28 CST 2017, time=2017-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=266230, encodeId=0083266230ec, content=^_^^_^^_^, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Swp2ehfHpiciczeTntUyQOlIGMzQ705ic67sdMTVMbwTv7KbmlUvxrGvRSvQZjPkz7ib5tEDfIaORgczPtmHDpwojg/0, createdBy=c54b2163125, createdName=wqkm, createdTime=Sat Dec 02 18:47:04 CST 2017, time=2017-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=266179, encodeId=70952661e9da, content=加強监管力度.保证用药安全, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Sat Dec 02 10:56:15 CST 2017, time=2017-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=266162, encodeId=5224266162b9, content=学习了新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Sat Dec 02 10:22:55 CST 2017, time=2017-12-02, status=1, ipAttribution=)]
    2018-07-21 Sometimes1575

    学习了

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=333170, encodeId=148b3331e039, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/07/07/1452f599cfa32a40733fa16ccf8ff86f.jpg, createdBy=d7452387169, createdName=Sometimes1575, createdTime=Sat Jul 21 16:38:48 CST 2018, time=2018-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1668094, encodeId=49e9166809405, content=<a href='/topic/show?id=598b40158ff' target=_blank style='color:#2F92EE;'>#喜炎平#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40158, encryptionId=598b40158ff, topicName=喜炎平)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e0f926261460, createdName=tamgche, createdTime=Mon Jun 04 02:58:00 CST 2018, time=2018-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1648669, encodeId=44651648669cc, content=<a href='/topic/show?id=e037891284c' target=_blank style='color:#2F92EE;'>#血栓通#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89128, encryptionId=e037891284c, topicName=血栓通)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=051423632604, createdName=cathymary, createdTime=Fri Dec 08 09:58:00 CST 2017, time=2017-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1949080, encodeId=27b4194908032, content=<a href='/topic/show?id=72459589567' target=_blank style='color:#2F92EE;'>#重点监控#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95895, encryptionId=72459589567, topicName=重点监控)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93e223, createdName=bluefate121, createdTime=Tue Dec 12 22:58:00 CST 2017, time=2017-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=273265, encodeId=0d8b2e326551, content=谢谢分享.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160304/IMG56D94856B1B5D6405.jpg, createdBy=27931687771, createdName=一个字-牛, createdTime=Thu Dec 28 16:59:15 CST 2017, time=2017-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=267237, encodeId=b29226e23769, content=好好好学习学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM6DGOvNrRdcib3UmzMgpEQpl0ENSJScphsFtdgfibXX1g1IuEYGCjP23UqCd52TxTpSZibtPiclyusaHicnNXd78alaia19Qy1nAFo18/0, createdBy=50381491660, createdName=zwjnj2, createdTime=Wed Dec 06 10:59:03 CST 2017, time=2017-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=266347, encodeId=a60526634e1b, content=这些药品是谁审批.让进入临床的, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/21/9461f3b3c9f14e1d844256cdd08f2cf3.jpg, createdBy=a30f1426910, createdName=swfzhanggui, createdTime=Sun Dec 03 05:06:28 CST 2017, time=2017-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=266230, encodeId=0083266230ec, content=^_^^_^^_^, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Swp2ehfHpiciczeTntUyQOlIGMzQ705ic67sdMTVMbwTv7KbmlUvxrGvRSvQZjPkz7ib5tEDfIaORgczPtmHDpwojg/0, createdBy=c54b2163125, createdName=wqkm, createdTime=Sat Dec 02 18:47:04 CST 2017, time=2017-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=266179, encodeId=70952661e9da, content=加強监管力度.保证用药安全, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Sat Dec 02 10:56:15 CST 2017, time=2017-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=266162, encodeId=5224266162b9, content=学习了新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Sat Dec 02 10:22:55 CST 2017, time=2017-12-02, status=1, ipAttribution=)]
    2018-06-04 tamgche
  3. [GetPortalCommentsPageByObjectIdResponse(id=333170, encodeId=148b3331e039, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/07/07/1452f599cfa32a40733fa16ccf8ff86f.jpg, createdBy=d7452387169, createdName=Sometimes1575, createdTime=Sat Jul 21 16:38:48 CST 2018, time=2018-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1668094, encodeId=49e9166809405, content=<a href='/topic/show?id=598b40158ff' target=_blank style='color:#2F92EE;'>#喜炎平#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40158, encryptionId=598b40158ff, topicName=喜炎平)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e0f926261460, createdName=tamgche, createdTime=Mon Jun 04 02:58:00 CST 2018, time=2018-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1648669, encodeId=44651648669cc, content=<a href='/topic/show?id=e037891284c' target=_blank style='color:#2F92EE;'>#血栓通#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89128, encryptionId=e037891284c, topicName=血栓通)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=051423632604, createdName=cathymary, createdTime=Fri Dec 08 09:58:00 CST 2017, time=2017-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1949080, encodeId=27b4194908032, content=<a href='/topic/show?id=72459589567' target=_blank style='color:#2F92EE;'>#重点监控#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95895, encryptionId=72459589567, topicName=重点监控)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93e223, createdName=bluefate121, createdTime=Tue Dec 12 22:58:00 CST 2017, time=2017-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=273265, encodeId=0d8b2e326551, content=谢谢分享.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160304/IMG56D94856B1B5D6405.jpg, createdBy=27931687771, createdName=一个字-牛, createdTime=Thu Dec 28 16:59:15 CST 2017, time=2017-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=267237, encodeId=b29226e23769, content=好好好学习学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM6DGOvNrRdcib3UmzMgpEQpl0ENSJScphsFtdgfibXX1g1IuEYGCjP23UqCd52TxTpSZibtPiclyusaHicnNXd78alaia19Qy1nAFo18/0, createdBy=50381491660, createdName=zwjnj2, createdTime=Wed Dec 06 10:59:03 CST 2017, time=2017-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=266347, encodeId=a60526634e1b, content=这些药品是谁审批.让进入临床的, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/21/9461f3b3c9f14e1d844256cdd08f2cf3.jpg, createdBy=a30f1426910, createdName=swfzhanggui, createdTime=Sun Dec 03 05:06:28 CST 2017, time=2017-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=266230, encodeId=0083266230ec, content=^_^^_^^_^, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Swp2ehfHpiciczeTntUyQOlIGMzQ705ic67sdMTVMbwTv7KbmlUvxrGvRSvQZjPkz7ib5tEDfIaORgczPtmHDpwojg/0, createdBy=c54b2163125, createdName=wqkm, createdTime=Sat Dec 02 18:47:04 CST 2017, time=2017-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=266179, encodeId=70952661e9da, content=加強监管力度.保证用药安全, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Sat Dec 02 10:56:15 CST 2017, time=2017-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=266162, encodeId=5224266162b9, content=学习了新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Sat Dec 02 10:22:55 CST 2017, time=2017-12-02, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=333170, encodeId=148b3331e039, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/07/07/1452f599cfa32a40733fa16ccf8ff86f.jpg, createdBy=d7452387169, createdName=Sometimes1575, createdTime=Sat Jul 21 16:38:48 CST 2018, time=2018-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1668094, encodeId=49e9166809405, content=<a href='/topic/show?id=598b40158ff' target=_blank style='color:#2F92EE;'>#喜炎平#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40158, encryptionId=598b40158ff, topicName=喜炎平)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e0f926261460, createdName=tamgche, createdTime=Mon Jun 04 02:58:00 CST 2018, time=2018-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1648669, encodeId=44651648669cc, content=<a href='/topic/show?id=e037891284c' target=_blank style='color:#2F92EE;'>#血栓通#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89128, encryptionId=e037891284c, topicName=血栓通)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=051423632604, createdName=cathymary, createdTime=Fri Dec 08 09:58:00 CST 2017, time=2017-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1949080, encodeId=27b4194908032, content=<a href='/topic/show?id=72459589567' target=_blank style='color:#2F92EE;'>#重点监控#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95895, encryptionId=72459589567, topicName=重点监控)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93e223, createdName=bluefate121, createdTime=Tue Dec 12 22:58:00 CST 2017, time=2017-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=273265, encodeId=0d8b2e326551, content=谢谢分享.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160304/IMG56D94856B1B5D6405.jpg, createdBy=27931687771, createdName=一个字-牛, createdTime=Thu Dec 28 16:59:15 CST 2017, time=2017-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=267237, encodeId=b29226e23769, content=好好好学习学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM6DGOvNrRdcib3UmzMgpEQpl0ENSJScphsFtdgfibXX1g1IuEYGCjP23UqCd52TxTpSZibtPiclyusaHicnNXd78alaia19Qy1nAFo18/0, createdBy=50381491660, createdName=zwjnj2, createdTime=Wed Dec 06 10:59:03 CST 2017, time=2017-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=266347, encodeId=a60526634e1b, content=这些药品是谁审批.让进入临床的, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/21/9461f3b3c9f14e1d844256cdd08f2cf3.jpg, createdBy=a30f1426910, createdName=swfzhanggui, createdTime=Sun Dec 03 05:06:28 CST 2017, time=2017-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=266230, encodeId=0083266230ec, content=^_^^_^^_^, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Swp2ehfHpiciczeTntUyQOlIGMzQ705ic67sdMTVMbwTv7KbmlUvxrGvRSvQZjPkz7ib5tEDfIaORgczPtmHDpwojg/0, createdBy=c54b2163125, createdName=wqkm, createdTime=Sat Dec 02 18:47:04 CST 2017, time=2017-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=266179, encodeId=70952661e9da, content=加強监管力度.保证用药安全, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Sat Dec 02 10:56:15 CST 2017, time=2017-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=266162, encodeId=5224266162b9, content=学习了新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Sat Dec 02 10:22:55 CST 2017, time=2017-12-02, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=333170, encodeId=148b3331e039, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/07/07/1452f599cfa32a40733fa16ccf8ff86f.jpg, createdBy=d7452387169, createdName=Sometimes1575, createdTime=Sat Jul 21 16:38:48 CST 2018, time=2018-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1668094, encodeId=49e9166809405, content=<a href='/topic/show?id=598b40158ff' target=_blank style='color:#2F92EE;'>#喜炎平#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40158, encryptionId=598b40158ff, topicName=喜炎平)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e0f926261460, createdName=tamgche, createdTime=Mon Jun 04 02:58:00 CST 2018, time=2018-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1648669, encodeId=44651648669cc, content=<a href='/topic/show?id=e037891284c' target=_blank style='color:#2F92EE;'>#血栓通#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89128, encryptionId=e037891284c, topicName=血栓通)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=051423632604, createdName=cathymary, createdTime=Fri Dec 08 09:58:00 CST 2017, time=2017-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1949080, encodeId=27b4194908032, content=<a href='/topic/show?id=72459589567' target=_blank style='color:#2F92EE;'>#重点监控#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95895, encryptionId=72459589567, topicName=重点监控)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93e223, createdName=bluefate121, createdTime=Tue Dec 12 22:58:00 CST 2017, time=2017-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=273265, encodeId=0d8b2e326551, content=谢谢分享.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160304/IMG56D94856B1B5D6405.jpg, createdBy=27931687771, createdName=一个字-牛, createdTime=Thu Dec 28 16:59:15 CST 2017, time=2017-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=267237, encodeId=b29226e23769, content=好好好学习学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM6DGOvNrRdcib3UmzMgpEQpl0ENSJScphsFtdgfibXX1g1IuEYGCjP23UqCd52TxTpSZibtPiclyusaHicnNXd78alaia19Qy1nAFo18/0, createdBy=50381491660, createdName=zwjnj2, createdTime=Wed Dec 06 10:59:03 CST 2017, time=2017-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=266347, encodeId=a60526634e1b, content=这些药品是谁审批.让进入临床的, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/21/9461f3b3c9f14e1d844256cdd08f2cf3.jpg, createdBy=a30f1426910, createdName=swfzhanggui, createdTime=Sun Dec 03 05:06:28 CST 2017, time=2017-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=266230, encodeId=0083266230ec, content=^_^^_^^_^, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Swp2ehfHpiciczeTntUyQOlIGMzQ705ic67sdMTVMbwTv7KbmlUvxrGvRSvQZjPkz7ib5tEDfIaORgczPtmHDpwojg/0, createdBy=c54b2163125, createdName=wqkm, createdTime=Sat Dec 02 18:47:04 CST 2017, time=2017-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=266179, encodeId=70952661e9da, content=加強监管力度.保证用药安全, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Sat Dec 02 10:56:15 CST 2017, time=2017-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=266162, encodeId=5224266162b9, content=学习了新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Sat Dec 02 10:22:55 CST 2017, time=2017-12-02, status=1, ipAttribution=)]
    2017-12-28 一个字-牛

    谢谢分享.学习了

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=333170, encodeId=148b3331e039, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/07/07/1452f599cfa32a40733fa16ccf8ff86f.jpg, createdBy=d7452387169, createdName=Sometimes1575, createdTime=Sat Jul 21 16:38:48 CST 2018, time=2018-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1668094, encodeId=49e9166809405, content=<a href='/topic/show?id=598b40158ff' target=_blank style='color:#2F92EE;'>#喜炎平#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40158, encryptionId=598b40158ff, topicName=喜炎平)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e0f926261460, createdName=tamgche, createdTime=Mon Jun 04 02:58:00 CST 2018, time=2018-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1648669, encodeId=44651648669cc, content=<a href='/topic/show?id=e037891284c' target=_blank style='color:#2F92EE;'>#血栓通#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89128, encryptionId=e037891284c, topicName=血栓通)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=051423632604, createdName=cathymary, createdTime=Fri Dec 08 09:58:00 CST 2017, time=2017-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1949080, encodeId=27b4194908032, content=<a href='/topic/show?id=72459589567' target=_blank style='color:#2F92EE;'>#重点监控#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95895, encryptionId=72459589567, topicName=重点监控)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93e223, createdName=bluefate121, createdTime=Tue Dec 12 22:58:00 CST 2017, time=2017-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=273265, encodeId=0d8b2e326551, content=谢谢分享.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160304/IMG56D94856B1B5D6405.jpg, createdBy=27931687771, createdName=一个字-牛, createdTime=Thu Dec 28 16:59:15 CST 2017, time=2017-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=267237, encodeId=b29226e23769, content=好好好学习学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM6DGOvNrRdcib3UmzMgpEQpl0ENSJScphsFtdgfibXX1g1IuEYGCjP23UqCd52TxTpSZibtPiclyusaHicnNXd78alaia19Qy1nAFo18/0, createdBy=50381491660, createdName=zwjnj2, createdTime=Wed Dec 06 10:59:03 CST 2017, time=2017-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=266347, encodeId=a60526634e1b, content=这些药品是谁审批.让进入临床的, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/21/9461f3b3c9f14e1d844256cdd08f2cf3.jpg, createdBy=a30f1426910, createdName=swfzhanggui, createdTime=Sun Dec 03 05:06:28 CST 2017, time=2017-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=266230, encodeId=0083266230ec, content=^_^^_^^_^, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Swp2ehfHpiciczeTntUyQOlIGMzQ705ic67sdMTVMbwTv7KbmlUvxrGvRSvQZjPkz7ib5tEDfIaORgczPtmHDpwojg/0, createdBy=c54b2163125, createdName=wqkm, createdTime=Sat Dec 02 18:47:04 CST 2017, time=2017-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=266179, encodeId=70952661e9da, content=加強监管力度.保证用药安全, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Sat Dec 02 10:56:15 CST 2017, time=2017-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=266162, encodeId=5224266162b9, content=学习了新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Sat Dec 02 10:22:55 CST 2017, time=2017-12-02, status=1, ipAttribution=)]
    2017-12-06 zwjnj2

    好好好学习学习学习

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=333170, encodeId=148b3331e039, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/07/07/1452f599cfa32a40733fa16ccf8ff86f.jpg, createdBy=d7452387169, createdName=Sometimes1575, createdTime=Sat Jul 21 16:38:48 CST 2018, time=2018-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1668094, encodeId=49e9166809405, content=<a href='/topic/show?id=598b40158ff' target=_blank style='color:#2F92EE;'>#喜炎平#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40158, encryptionId=598b40158ff, topicName=喜炎平)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e0f926261460, createdName=tamgche, createdTime=Mon Jun 04 02:58:00 CST 2018, time=2018-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1648669, encodeId=44651648669cc, content=<a href='/topic/show?id=e037891284c' target=_blank style='color:#2F92EE;'>#血栓通#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89128, encryptionId=e037891284c, topicName=血栓通)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=051423632604, createdName=cathymary, createdTime=Fri Dec 08 09:58:00 CST 2017, time=2017-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1949080, encodeId=27b4194908032, content=<a href='/topic/show?id=72459589567' target=_blank style='color:#2F92EE;'>#重点监控#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95895, encryptionId=72459589567, topicName=重点监控)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93e223, createdName=bluefate121, createdTime=Tue Dec 12 22:58:00 CST 2017, time=2017-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=273265, encodeId=0d8b2e326551, content=谢谢分享.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160304/IMG56D94856B1B5D6405.jpg, createdBy=27931687771, createdName=一个字-牛, createdTime=Thu Dec 28 16:59:15 CST 2017, time=2017-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=267237, encodeId=b29226e23769, content=好好好学习学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM6DGOvNrRdcib3UmzMgpEQpl0ENSJScphsFtdgfibXX1g1IuEYGCjP23UqCd52TxTpSZibtPiclyusaHicnNXd78alaia19Qy1nAFo18/0, createdBy=50381491660, createdName=zwjnj2, createdTime=Wed Dec 06 10:59:03 CST 2017, time=2017-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=266347, encodeId=a60526634e1b, content=这些药品是谁审批.让进入临床的, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/21/9461f3b3c9f14e1d844256cdd08f2cf3.jpg, createdBy=a30f1426910, createdName=swfzhanggui, createdTime=Sun Dec 03 05:06:28 CST 2017, time=2017-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=266230, encodeId=0083266230ec, content=^_^^_^^_^, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Swp2ehfHpiciczeTntUyQOlIGMzQ705ic67sdMTVMbwTv7KbmlUvxrGvRSvQZjPkz7ib5tEDfIaORgczPtmHDpwojg/0, createdBy=c54b2163125, createdName=wqkm, createdTime=Sat Dec 02 18:47:04 CST 2017, time=2017-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=266179, encodeId=70952661e9da, content=加強监管力度.保证用药安全, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Sat Dec 02 10:56:15 CST 2017, time=2017-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=266162, encodeId=5224266162b9, content=学习了新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Sat Dec 02 10:22:55 CST 2017, time=2017-12-02, status=1, ipAttribution=)]
    2017-12-03 swfzhanggui

    这些药品是谁审批.让进入临床的

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=333170, encodeId=148b3331e039, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/07/07/1452f599cfa32a40733fa16ccf8ff86f.jpg, createdBy=d7452387169, createdName=Sometimes1575, createdTime=Sat Jul 21 16:38:48 CST 2018, time=2018-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1668094, encodeId=49e9166809405, content=<a href='/topic/show?id=598b40158ff' target=_blank style='color:#2F92EE;'>#喜炎平#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40158, encryptionId=598b40158ff, topicName=喜炎平)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e0f926261460, createdName=tamgche, createdTime=Mon Jun 04 02:58:00 CST 2018, time=2018-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1648669, encodeId=44651648669cc, content=<a href='/topic/show?id=e037891284c' target=_blank style='color:#2F92EE;'>#血栓通#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89128, encryptionId=e037891284c, topicName=血栓通)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=051423632604, createdName=cathymary, createdTime=Fri Dec 08 09:58:00 CST 2017, time=2017-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1949080, encodeId=27b4194908032, content=<a href='/topic/show?id=72459589567' target=_blank style='color:#2F92EE;'>#重点监控#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95895, encryptionId=72459589567, topicName=重点监控)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93e223, createdName=bluefate121, createdTime=Tue Dec 12 22:58:00 CST 2017, time=2017-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=273265, encodeId=0d8b2e326551, content=谢谢分享.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160304/IMG56D94856B1B5D6405.jpg, createdBy=27931687771, createdName=一个字-牛, createdTime=Thu Dec 28 16:59:15 CST 2017, time=2017-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=267237, encodeId=b29226e23769, content=好好好学习学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM6DGOvNrRdcib3UmzMgpEQpl0ENSJScphsFtdgfibXX1g1IuEYGCjP23UqCd52TxTpSZibtPiclyusaHicnNXd78alaia19Qy1nAFo18/0, createdBy=50381491660, createdName=zwjnj2, createdTime=Wed Dec 06 10:59:03 CST 2017, time=2017-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=266347, encodeId=a60526634e1b, content=这些药品是谁审批.让进入临床的, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/21/9461f3b3c9f14e1d844256cdd08f2cf3.jpg, createdBy=a30f1426910, createdName=swfzhanggui, createdTime=Sun Dec 03 05:06:28 CST 2017, time=2017-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=266230, encodeId=0083266230ec, content=^_^^_^^_^, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Swp2ehfHpiciczeTntUyQOlIGMzQ705ic67sdMTVMbwTv7KbmlUvxrGvRSvQZjPkz7ib5tEDfIaORgczPtmHDpwojg/0, createdBy=c54b2163125, createdName=wqkm, createdTime=Sat Dec 02 18:47:04 CST 2017, time=2017-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=266179, encodeId=70952661e9da, content=加強监管力度.保证用药安全, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Sat Dec 02 10:56:15 CST 2017, time=2017-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=266162, encodeId=5224266162b9, content=学习了新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Sat Dec 02 10:22:55 CST 2017, time=2017-12-02, status=1, ipAttribution=)]
    2017-12-02 wqkm

    ^_^^_^^_^

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=333170, encodeId=148b3331e039, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/07/07/1452f599cfa32a40733fa16ccf8ff86f.jpg, createdBy=d7452387169, createdName=Sometimes1575, createdTime=Sat Jul 21 16:38:48 CST 2018, time=2018-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1668094, encodeId=49e9166809405, content=<a href='/topic/show?id=598b40158ff' target=_blank style='color:#2F92EE;'>#喜炎平#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40158, encryptionId=598b40158ff, topicName=喜炎平)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e0f926261460, createdName=tamgche, createdTime=Mon Jun 04 02:58:00 CST 2018, time=2018-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1648669, encodeId=44651648669cc, content=<a href='/topic/show?id=e037891284c' target=_blank style='color:#2F92EE;'>#血栓通#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89128, encryptionId=e037891284c, topicName=血栓通)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=051423632604, createdName=cathymary, createdTime=Fri Dec 08 09:58:00 CST 2017, time=2017-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1949080, encodeId=27b4194908032, content=<a href='/topic/show?id=72459589567' target=_blank style='color:#2F92EE;'>#重点监控#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95895, encryptionId=72459589567, topicName=重点监控)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93e223, createdName=bluefate121, createdTime=Tue Dec 12 22:58:00 CST 2017, time=2017-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=273265, encodeId=0d8b2e326551, content=谢谢分享.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160304/IMG56D94856B1B5D6405.jpg, createdBy=27931687771, createdName=一个字-牛, createdTime=Thu Dec 28 16:59:15 CST 2017, time=2017-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=267237, encodeId=b29226e23769, content=好好好学习学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM6DGOvNrRdcib3UmzMgpEQpl0ENSJScphsFtdgfibXX1g1IuEYGCjP23UqCd52TxTpSZibtPiclyusaHicnNXd78alaia19Qy1nAFo18/0, createdBy=50381491660, createdName=zwjnj2, createdTime=Wed Dec 06 10:59:03 CST 2017, time=2017-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=266347, encodeId=a60526634e1b, content=这些药品是谁审批.让进入临床的, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/21/9461f3b3c9f14e1d844256cdd08f2cf3.jpg, createdBy=a30f1426910, createdName=swfzhanggui, createdTime=Sun Dec 03 05:06:28 CST 2017, time=2017-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=266230, encodeId=0083266230ec, content=^_^^_^^_^, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Swp2ehfHpiciczeTntUyQOlIGMzQ705ic67sdMTVMbwTv7KbmlUvxrGvRSvQZjPkz7ib5tEDfIaORgczPtmHDpwojg/0, createdBy=c54b2163125, createdName=wqkm, createdTime=Sat Dec 02 18:47:04 CST 2017, time=2017-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=266179, encodeId=70952661e9da, content=加強监管力度.保证用药安全, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Sat Dec 02 10:56:15 CST 2017, time=2017-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=266162, encodeId=5224266162b9, content=学习了新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Sat Dec 02 10:22:55 CST 2017, time=2017-12-02, status=1, ipAttribution=)]
    2017-12-02 1e0f8808m18(暂无匿称)

    加強监管力度.保证用药安全

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=333170, encodeId=148b3331e039, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/07/07/1452f599cfa32a40733fa16ccf8ff86f.jpg, createdBy=d7452387169, createdName=Sometimes1575, createdTime=Sat Jul 21 16:38:48 CST 2018, time=2018-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1668094, encodeId=49e9166809405, content=<a href='/topic/show?id=598b40158ff' target=_blank style='color:#2F92EE;'>#喜炎平#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40158, encryptionId=598b40158ff, topicName=喜炎平)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e0f926261460, createdName=tamgche, createdTime=Mon Jun 04 02:58:00 CST 2018, time=2018-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1648669, encodeId=44651648669cc, content=<a href='/topic/show?id=e037891284c' target=_blank style='color:#2F92EE;'>#血栓通#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89128, encryptionId=e037891284c, topicName=血栓通)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=051423632604, createdName=cathymary, createdTime=Fri Dec 08 09:58:00 CST 2017, time=2017-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1949080, encodeId=27b4194908032, content=<a href='/topic/show?id=72459589567' target=_blank style='color:#2F92EE;'>#重点监控#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95895, encryptionId=72459589567, topicName=重点监控)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93e223, createdName=bluefate121, createdTime=Tue Dec 12 22:58:00 CST 2017, time=2017-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=273265, encodeId=0d8b2e326551, content=谢谢分享.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160304/IMG56D94856B1B5D6405.jpg, createdBy=27931687771, createdName=一个字-牛, createdTime=Thu Dec 28 16:59:15 CST 2017, time=2017-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=267237, encodeId=b29226e23769, content=好好好学习学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM6DGOvNrRdcib3UmzMgpEQpl0ENSJScphsFtdgfibXX1g1IuEYGCjP23UqCd52TxTpSZibtPiclyusaHicnNXd78alaia19Qy1nAFo18/0, createdBy=50381491660, createdName=zwjnj2, createdTime=Wed Dec 06 10:59:03 CST 2017, time=2017-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=266347, encodeId=a60526634e1b, content=这些药品是谁审批.让进入临床的, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/21/9461f3b3c9f14e1d844256cdd08f2cf3.jpg, createdBy=a30f1426910, createdName=swfzhanggui, createdTime=Sun Dec 03 05:06:28 CST 2017, time=2017-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=266230, encodeId=0083266230ec, content=^_^^_^^_^, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Swp2ehfHpiciczeTntUyQOlIGMzQ705ic67sdMTVMbwTv7KbmlUvxrGvRSvQZjPkz7ib5tEDfIaORgczPtmHDpwojg/0, createdBy=c54b2163125, createdName=wqkm, createdTime=Sat Dec 02 18:47:04 CST 2017, time=2017-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=266179, encodeId=70952661e9da, content=加強监管力度.保证用药安全, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Sat Dec 02 10:56:15 CST 2017, time=2017-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=266162, encodeId=5224266162b9, content=学习了新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Sat Dec 02 10:22:55 CST 2017, time=2017-12-02, status=1, ipAttribution=)]
    2017-12-02 Y—xianghai

    学习了新知识

    0

相关资讯

总局公告,5产品修订说明书,涉14家药企

11月29日,国家食药监总局发布公告,修订注射用脂溶性维生素(Ⅰ)等5个品种说明书。昨日,总局曾公告修订生脉注射液的说明书。

谈判药品进得了医保 想进医院却不简单

最近,媒体反映,经过谈判进入医保目录的药品却进不了医院,药企惊呼:砸了钱也没换来想要的。这到底是怎么回事?2017年7月由人社部组织专家进行了第二轮药品价格谈判,共有36个药品谈判成功,被纳入国家乙级医保目录。为了确保下了很大气力谈判成功的36种药品能够顺利进入医疗机构,国家卫计委、人社部就此专门下发了《关于做好36种谈判药品集中采购的通知》(国卫办药政函〔2017〕856号),各省卫计委药政管理

黑龙江完善药品生产流通使用政策

近日,黑龙江省出台《关于进一步改革完善全省药品生产流通使用政策的实施意见》,要求提高药品质量疗效,推动医药产业供给侧结构性改革。坚持监测哨点定期报告制度,建立短缺药品监测常态机制。

新版艾滋病国家免费用药目录或月底出台

近日,在业界独家获得消息,已经施行超过十年的国家艾滋病免费药物目录将迎来一次重大调整。消息称国家卫计委正在讨论新一版艾滋病国家免费用药目录的修订,并且已召集数家艾滋病药品生产企业进行询价,预计有望在本月底确定最终目录。

重磅:发改委:提升中高端医疗器械和药品供给能力

国家发改委日前印发《增强制造业核心竞争力三年行动计划(2018-2020年)》,聚焦包括“高端医疗器械和药品”在内的9大重点领域,提出增强制造业核心竞争力,推动我国制造业加快迈向全球价值链中高端。《计划》强调,组织实施高端医疗器械和药品领域关键技术产业化专项,提升中高端医疗器械和药品供给能力,保障人民群众就医用药需求。

秦环龙:谋变药品零加成时代

药品零加成改变了医院的经济运行模式,政策框架已经形成,如何以最快的速度响应政策,同时又能兼顾医院发展,是摆在每位医院管理者面前的现实问题。业务量已经不是评价现代医院的唯一指标,未来,更多的关注点要转移到医院学科能力和诊疗能力的提升上。从量到质的转变药品零加成后,医院发展面临的挑战主要有几个方面:其一,由过去单纯追求业务量增长到兼顾技术提升和关键疗效指标改善。过去7天~8天的收入能不能在3天~5天就